Updated:
Synlogic
Synlogic, a clinical-stage synthetic biology firm, engineered living probiotic medicines for metabolic diseases until its 2023 acquisition by Ginkgo...
Synlogic
Synlogic was incorporated in 2014 as a spinout from MIT's synthetic biology program, founded by researchers including Professor James Collins and venture capital partner Neil Goldsmith. The company went public via a reverse merger with Concert Pharmaceuticals in 2017, trading under the ticker SYBX until its acquisition by Ginkgo Bioworks in 2023. Its wealth origin derived from institutional venture capital and public market investors, with no disclosed family-office backing. The firm pioneered a platform for engineering probiotic bacteria — specifically strains of E. coli Nissle and L. lactis — as living therapeutic delivery systems. Its lead pipeline included candidate SYNB1934 for phenylketonuria (PKU), a rare metabolic disorder, and SYNB8802 for enteric hyperoxaluria. Both programs reached Phase 2 clinical trials. Synlogic also established co-development partnerships with Roche for inflammatory bowel disease therapeutics and with the Bill & Melinda Gates Foundation for enteric pathogen-focused projects (per Synlogic SEC filings, 2020-2022). At its peak, Synlogic employed approximately 70 professionals, operating from a single headquarters in Cambridge, Massachusetts. The company managed no adjacent philanthropic structures or operating businesses distinct from its core drug development. In October 2023, Ginkgo Bioworks acquired Synlogic for an upfront payment of $10 million, with additional contingent value rights tied to pipeline milestones (per Ginkgo Bioworks press release, October 2023). The acquisition integrated Synlogic's synthetic biology platform into Ginkgo's broader cell programming infrastructure. Synlogic's structural differentiator was its use of whole-cell probiotic chassis rather than viral vectors or synthetic nanoparticles for therapeutic delivery — a regulatory and manufacturing path less trodden by the biotech sector. The company's dissolution through acquisition rather than drug approval left its platform and clinical assets under Ginkgo's control, with no independent entity continuing the brand.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who founded Synlogic and what was the scientific basis?
Synlogic was founded in 2014 as a spinout from MIT, with key founders including Professor James Collins, a pioneer in synthetic biology, and venture capital partner Neil Goldsmith. The scientific basis was engineering probiotic bacteria — specifically E. coli Nissle and L. lactis — to serve as living therapeutic delivery vehicles that can sense disease markers in the gut and produce therapeutic compounds on-site (per MIT media, 2014).
What clinical programs did Synlogic advance before its acquisition?
Synlogic advanced two lead programs into Phase 2 clinical trials: SYNB1934 for phenylketonuria (PKU), a rare metabolic disorder where patients cannot break down the amino acid phenylalanine, and SYNB8802 for enteric hyperoxaluria, a condition causing oxalate buildup. Both programs aimed to degrade target metabolites in the gut rather than in the bloodstream (per Synlogic SEC filings, 2022).
How did Synlogic's platform differ from traditional biotech approaches?
Unlike conventional biotech firms that use small molecules, antibodies, or gene therapies, Synlogic's platform used engineered living probiotic bacteria as therapeutic delivery systems. The bacteria were designed to sense specific gut conditions, such as elevated metabolite levels, and then produce and release therapeutic compounds. This 'living medicine' approach required novel regulatory pathways and manufacturing methods distinct from sterile synthetic drugs (per Synlogic corporate presentations, 2021).
What was the outcome of the Ginkgo Bioworks acquisition for Synlogic's pipeline?
Ginkgo Bioworks acquired Synlogic in October 2023 for $10 million in upfront stock consideration, plus contingent value rights of up to $10 million per clinical milestone for certain programs. The acquisition integrated Synlogic's synthetic biology platform into Ginkgo's cell programming infrastructure, with Ginkgo absorbing Synlogic's engineered probiotic technology and clinical-stage programs (per Ginkgo Bioworks press release, October 2023).
Did Synlogic have any partnerships beyond its acquisition by Ginkgo?
Yes. Synlogic established a co-development partnership with Roche in 2021 for inflammatory bowel disease therapeutics, using Synlogic's platform to identify and develop living medicines targeting the gut. Additionally, the firm had a collaboration with the Bill & Melinda Gates Foundation, funded by a series of grants, to develop oral probiotic therapies for enteric pathogens (per Synlogic SEC filings, 2022).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: